Cervical cancer diagnostics market seen topping $13 billion by 2030

The cervical cancer diagnostics market is projected to grow 6% annually through 2030, driven by wider screening, HPV testing and AI-assisted cytology. Roche leads the market today, while Pap smear tests remain the biggest segment.

Why it matters: - Cervical cancer diagnostics is expanding alongside broader cancer screening demand and new testing technology. - The market’s growth matters for hospitals, labs, and screening programs that are trying to detect disease earlier and improve follow-up care. - The segment is projected to exceed $13 billion by 2030, making it a meaningful slice of the wider cancer diagnostics market.

What happened: - The Business Research Company said the cervical cancer diagnostics market is expected to grow at a 6% compound annual rate through 2030. - The report places the market at about 29% of the broader cancer diagnostics market by 2030. - North America is forecast to be the largest regional market in 2030, at $3.9 billion. - The United States is expected to be the top country market by 2030, at $3.4 billion. - F. Hoffmann-La Roche Ltd. held the leading global sales position in 2025 with a 7% share. - Hologic Inc. had the second-largest share in 2025 at 6%.

The details: - Pap smear tests are projected to remain the largest test category in 2030, at about 33% of the market and roughly $4 billion in value. - HPV tests, colposcopy, biopsy and endocervical curettage, and other diagnostic methods make up the rest of the market’s core test types. - North America’s growth is tied to broader adoption of HPV DNA and molecular tests, organized screening programs, AI-assisted cytology, digital pathology, and better lab infrastructure. - The U.S. market is being supported by risk-based screening guidelines, HPV self-sampling efforts, improved reimbursement for advanced tests, and coordination among healthcare providers and public health groups. - The report says the market is moderately fragmented, with the top 10 players accounting for 23% of revenue in 2025. - The top 10 companies in 2025 included Roche, Hologic, Becton Dickinson, Abbott, QIAGEN, Cepheid, Quest Diagnostics, Sysmex, Thermo Fisher Scientific, and Siemens Healthineers. - The report also lists other notable participants, including Carl Zeiss, Bio-Rad, BGI Genomics, PerkinElmer, NeoGenomics, Invitae, Guided Therapeutics, Arbor Vita, Zilico, and Micromedic Technologies. - The report segment breakdown also covers age groups below 21, 21 to 29, 30 to 65, and over 65, plus end users such as hospitals, specialty clinics, cancer and radiation therapy centers, and diagnostic centers. - The combined pap smear, HPV, colposcopy, biopsy and other test segments are forecast to add more than $3.1 billion in market value by 2030. - From 2025 to 2030, pap smear tests and HPV tests are each expected to grow by about $1 billion. - Over the same period, colposcopy is expected to rise by $0.5 billion, other tests by $0.4 billion, and biopsy-related diagnostics by $0.2 billion. - The report says demand is being driven by AI-assisted screening, population-wide testing in emerging markets, and minimally invasive tests with high sensitivity. - Hologic received FDA clearance in February 2024 for its Genius Digital Diagnostics System, which includes the Genius Cervical AI algorithm. - The report says the company’s digital AI-powered diagnostic systems are improving screening precision, workflow efficiency, and earlier detection of precancerous conditions.

Between the lines: - The market’s growth is being driven less by one breakthrough and more by a stack of shifts: more routine screening, better automation, and broader access to molecular testing. - Roche’s lead shows that established diagnostics companies still dominate, but the market is open enough for competitors to gain share through AI, self-sampling, and automated platforms. - The heavy concentration in the top 10 names suggests a market that is competitive but still governed by regulatory and validation barriers. - The report’s emphasis on precision medicine points to a longer-term shift from simple screening toward more personalized risk assessment and follow-up.

What's next: - The report expects continued growth in HPV testing, molecular diagnostics, digital cytology, and AI-assisted workflows through 2030. - Companies are likely to keep pushing self-sampling tools, integrated screening platforms, and automated lab systems to expand access and improve throughput. - The Business Research Company also highlighted future report features including TAM analysis, company scoring matrices, forecasting dashboards, hotspots infographics, and updated graphics and tables.

The bottom line: - Cervical cancer diagnostics is moving from a screening niche into a larger, tech-driven diagnostics market, with AI and molecular testing likely to shape the next phase of growth. - More information